ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2018
Lycorine: A prospective natural lead for anticancer drug discovery.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 165 citations in OpenAlex.
- From Daffodils to Drug Leads: Amaryllidaceae Alkaloids Target Protein Translation in Chronic Lymphocytic Leukemia to Induce Selective Apoptosis.ACS pharmacology & translational science · 2026Article
- Lycorine inhibits the proliferation of acute myeloid leukemia cells by upregulating the expression of THBS1.Annals of hematology · 2026Article
- Amaryllidaceae Alkaloids and Phenolic Acids Identification inMolecules (Basel, Switzerland) · 2026Article
- Progress on new drug treatments for hepatic echinococcosis.Frontiers in pharmacology · 2026Review
- Sustainable formulations composed of biosurfactants and phytochemicals with potential application in fresh-cut food industry.Scientific reports · 2025Article
- Chinese medicine monomers for hepatocellular carcinoma: New ideas related to autophagy.World journal of gastroenterology · 2025Review
- Alkaloid Profile Characterisation and Bioactivity Evaluation of BolivianLife (Basel, Switzerland) · 2025Article
- Plant Alkaloids as Promising Anticancer Compounds with Blood-Brain Barrier Penetration in the Treatment of Glioblastoma: In Vitro and In Vivo Models.Molecules (Basel, Switzerland) · 2025Review
- Lycorine Pre-Treatment Alleviates Microglia Inflammation After Cerebral Ischemia by Inhibiting NF-κB Phosphorylation.Brain sciences · 2025Article
- Article
- Incredible use of plant-derived bioactives as anticancer agents.RSC advances · 2025Review
- Overcoming cancer drug resistance: insights into Apoptotic pathway modulation by plant-based nanoparticle and natural products.Frontiers in oncology · 2025Review
- Navigating Amaryllidaceae alkaloids: bridging gaps and charting biosynthetic territories.Journal of experimental botany · 2025Review
- Molecular Targets of Plant-based Alkaloids and Polyphenolics in Liver and Breast Cancer- An Insight into Anticancer Drug Development.Anti-cancer agents in medicinal chemistry · 2025Review
- Phytochemical and Cytotoxic Aspects of Amaryllidaceae Alkaloids inPlants (Basel, Switzerland) · 2024Review
- Advances of traditional Chinese medicine preclinical mechanisms and clinical studies on diabetic peripheral neuropathy.Pharmaceutical biology · 2024Review
- Protective effect of lycorine hydrochloride against diabetic nephropathy in high-fat diet and streptozotocin-induced diabetic mice.Pharmaceutical science advances · 2024Article
- Histochemical Localization and Cytotoxic Potential of Alkaloids inPlants (Basel, Switzerland) · 2024Article
- Multiple NADPH-cytochrome P450 reductases from Lycoris radiata involved in Amaryllidaceae alkaloids biosynthesis.Plant molecular biology · 2024Article
- Non-Nucleoside Lycorine-Based Analogs as Potential DENV/ZIKV NS5 Dual Inhibitors: Structure-Based Virtual Screening and Chemoinformatic Analysis.Metabolites · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nature is the most abundant source for novel drug discovery. Lycorine is a natural alkaloid with immense therapeutic potential. Lycorine is active in a very low concentration and with high specificity against a number of cancers both in vivo and in vitro and against various drug-resistant cancer cells. This review summarized the therapeutic effect and the anticancer mechanisms of lycorine. At the same time, we have discussed the pharmacology and comparative structure-activity relationship for the anticancer activity of this compound. The researches outlined in this paper serve as a foundation to explain lycorine as an important lead compound for new generation anticancer drug design and provide the principle for the development of biological strategies to utilize lycorine in the treatment of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.